ES2196082T3 - Analagos del factor de crecimiento de queratinocitos. - Google Patents

Analagos del factor de crecimiento de queratinocitos.

Info

Publication number
ES2196082T3
ES2196082T3 ES95934793T ES95934793T ES2196082T3 ES 2196082 T3 ES2196082 T3 ES 2196082T3 ES 95934793 T ES95934793 T ES 95934793T ES 95934793 T ES95934793 T ES 95934793T ES 2196082 T3 ES2196082 T3 ES 2196082T3
Authority
ES
Spain
Prior art keywords
amino acid
growth factor
analogs
queratinocit
analagos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95934793T
Other languages
English (en)
Inventor
Charles F Morris
William C Kenney
Bao-Lu Chen
Eric W Hsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ES2196082T3 publication Critical patent/ES2196082T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A ANALOGOS DE POLIPEPTIDO DE UN POTENTE MITOGENO DE CRECIMIENTO DE CELULA EPITELIAL NO FIBROBLASTICA, FACTOR DE CRECIMIENTO DE QUERATINOCITO (KGF) QUE TIENE HASTA LOS PRIMEROS 24 AMINOACIDOS N-TERMINALES MODIFICADOS EN DONDE RESIDUOS DE CISTEINA CORRESPONDIENTES A LAS POSICIONES DE AMINOACIDO 1 Y 15 DEL KGF [POSICIONES DE AMINOACIDO 32 Y 46 DEL N ENTE)] SON SUPRIMIDAS O SUSTITUIDAS POR OTRO AMINOACIDO. TAMBIEN SE DESCRIBEN MOLECULAS DE ACIDO NUCLEICO QUE CODIFICAN DICHOS ANALOGOS, ASI COMO METODOS DE UTILIZACION DE DICHOS ANALOGOS PARA ESTIMULAR LA PROLIFERACION DE CELULA EPITELIAL NO FIBROBLASTICA.
ES95934793T 1994-10-13 1995-10-12 Analagos del factor de crecimiento de queratinocitos. Expired - Lifetime ES2196082T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32334094A 1994-10-13 1994-10-13
US32347594A 1994-10-13 1994-10-13
US48782595A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ES2196082T3 true ES2196082T3 (es) 2003-12-16

Family

ID=27406268

Family Applications (2)

Application Number Title Priority Date Filing Date
ES95934793T Expired - Lifetime ES2196082T3 (es) 1994-10-13 1995-10-12 Analagos del factor de crecimiento de queratinocitos.
ES95934808T Expired - Lifetime ES2273338T3 (es) 1994-10-13 1995-10-12 Metodo para el tratamiento de la diabetes mellitus usando kfg.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES95934808T Expired - Lifetime ES2273338T3 (es) 1994-10-13 1995-10-12 Metodo para el tratamiento de la diabetes mellitus usando kfg.

Country Status (23)

Country Link
EP (2) EP0804479B1 (es)
JP (2) JP4216329B2 (es)
KR (1) KR100278597B1 (es)
CN (1) CN1168678A (es)
AT (2) ATE342278T1 (es)
AU (1) AU3707795A (es)
BG (2) BG101392A (es)
BR (2) BR9509329A (es)
CA (2) CA2202075C (es)
CZ (3) CZ297328B6 (es)
DE (2) DE69535264T2 (es)
DK (2) DK0785948T3 (es)
EE (2) EE03975B1 (es)
ES (2) ES2196082T3 (es)
FI (2) FI971420A7 (es)
HU (2) HU226168B1 (es)
NO (2) NO318761B1 (es)
NZ (2) NZ505502A (es)
PL (2) PL182888B1 (es)
PT (2) PT785948E (es)
SI (2) SI0804479T1 (es)
SK (2) SK284534B6 (es)
WO (2) WO1996011949A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2250213C2 (ru) 1989-01-31 2005-04-20 Джеффри С. РУБИН Выделенный белок фактора роста кератиноцита (kgf), рекомбинантная молекула днк, вектор, способ конструирования клетки-хозяина, способ получения белка, фармацевтическая композиция
CA2166278A1 (en) 1993-06-29 1995-01-12 Denis J. Gospodarowicz A truncated keratinocyte growth factor (kgf) having increased biological activity
US7084119B2 (en) 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
SI0785949T1 (en) * 1994-10-13 2003-08-31 Amgen Inc. Method for purifying keratinocyte growth factors
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
DE69603269T3 (de) * 1995-04-27 2007-02-22 Coöperatie Cosun U.A. Derivate von inulin
ES2218666T3 (es) * 1996-10-15 2004-11-16 Amgen Inc., Producto a base del factor de crecimiento de queratinocitos-2 (kggf-2).
SI0935652T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Keratinocyte growth factor-2 products
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
WO1999032135A1 (en) 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6242666B1 (en) 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CA2359345A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6248725B1 (en) 1999-02-23 2001-06-19 Amgen, Inc. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
CN1491231A (zh) * 2001-02-06 2004-04-21 Ĭ��ר�����޹�˾ 免疫原性减弱的经修饰角质形成细胞生长因子(kgf)
AU2002326742B2 (en) * 2001-08-21 2007-05-31 Novartis Vaccines And Diagnostics, Inc. KGF polypeptide compositions
AU2007214362B2 (en) * 2001-08-21 2009-11-26 Novartis Vaccines And Diagnostics, Inc. KGF polypeptide compositions
AU2005317166B2 (en) 2004-12-15 2009-09-10 Biovitrum Ab (Publ) Therapeutic formulations of keratinocyte growth factor
CN102242124B (zh) * 2010-05-10 2013-05-22 齐鲁制药有限公司 改造的角化细胞生长因子基因及其在酵母中的表达
KR102440312B1 (ko) * 2020-08-28 2022-09-05 한국해양과학기술원 온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JPH01137994A (ja) * 1987-08-10 1989-05-30 Shionogi & Co Ltd ｒｅｇ蛋白質
WO1990000877A1 (en) * 1988-07-27 1990-02-08 Marjan International Pty Ltd Carpet stretcher
RU2250213C2 (ru) * 1989-01-31 2005-04-20 Джеффри С. РУБИН Выделенный белок фактора роста кератиноцита (kgf), рекомбинантная молекула днк, вектор, способ конструирования клетки-хозяина, способ получения белка, фармацевтическая композиция
JP3303211B2 (ja) * 1991-04-26 2002-07-15 武田薬品工業株式会社 ｂＦＧＦムテインおよびその製造法
AU707340B2 (en) * 1993-03-26 1999-07-08 Biovitrum Ab (Publ) Therapeutic uses of keratinocyte growth factor
US5348563A (en) * 1993-06-29 1994-09-20 Honeywell Inc. Air purifying apparatus
CA2166278A1 (en) * 1993-06-29 1995-01-12 Denis J. Gospodarowicz A truncated keratinocyte growth factor (kgf) having increased biological activity
GB9315501D0 (en) * 1993-07-27 1993-09-08 Ici Plc Surfactant compositions
AU7475694A (en) * 1993-08-02 1995-02-28 Prizm Pharmaceuticals, Inc. Monogenous preparations of cytotoxic conjugates

Also Published As

Publication number Publication date
JP4426646B2 (ja) 2010-03-03
HUT78058A (hu) 1999-07-28
NZ335109A (en) 2000-08-25
WO1996011949A3 (en) 1996-12-12
PT785948E (pt) 2003-09-30
ES2273338T3 (es) 2007-05-01
CZ297328B6 (cs) 2006-11-15
HUT78050A (hu) 1999-07-28
AU3707795A (en) 1996-05-06
PL320484A1 (en) 1997-09-29
SI0804479T1 (sl) 2006-12-31
FI971420L (fi) 1997-04-04
ATE342278T1 (de) 2006-11-15
NO971566D0 (no) 1997-04-04
DE69530403D1 (de) 2003-05-22
CA2201940C (en) 2009-05-12
BR9509329A (pt) 1997-10-14
BG63167B1 (bg) 2001-05-31
PL182888B1 (pl) 2002-03-29
SK45597A3 (en) 1999-02-11
AU3708395A (en) 1996-05-06
EP0785948B1 (en) 2003-04-16
CZ105097A3 (cs) 1998-10-14
FI971420A0 (fi) 1997-04-04
FI971420A7 (fi) 1997-04-04
KR100278597B1 (ko) 2001-01-15
DK0804479T3 (da) 2007-01-29
SK43197A3 (en) 1999-03-12
CZ297329B6 (cs) 2006-11-15
JPH10507193A (ja) 1998-07-14
ATE237633T1 (de) 2003-05-15
NO318761B1 (no) 2005-05-02
JP4216329B2 (ja) 2009-01-28
NO971568D0 (no) 1997-04-04
EE03975B1 (et) 2003-02-17
HU226168B1 (en) 2008-05-28
DK0785948T3 (da) 2003-08-04
FI971536L (fi) 1997-06-09
CZ98197A3 (cs) 1998-11-11
PL319784A1 (en) 1997-08-18
JPH10507080A (ja) 1998-07-14
CA2201940A1 (en) 1996-04-25
BR9509269A (pt) 1997-12-23
PT804479E (pt) 2007-02-28
EP0804479B1 (en) 2006-10-11
FI971536A0 (fi) 1997-04-11
FI120040B (fi) 2009-06-15
EP0785948A1 (en) 1997-07-30
AU681546B2 (en) 1997-08-28
WO1996011950A1 (en) 1996-04-25
BG101392A (en) 1997-10-31
SI0785948T1 (en) 2003-08-31
CA2202075A1 (en) 1996-04-25
NO971566L (no) 1997-04-14
CN1168678A (zh) 1997-12-24
NZ505502A (en) 2005-01-28
EE9700225A (et) 1998-02-16
EP0804479A1 (en) 1997-11-05
CA2202075C (en) 2003-12-09
SK284534B6 (sk) 2005-06-02
DE69530403T2 (de) 2003-10-30
NO971568L (no) 1997-06-12
BG101408A (bg) 1997-12-30
DE69535264D1 (de) 2006-11-23
WO1996011949A2 (en) 1996-04-25
DE69535264T2 (de) 2007-02-01
EE9700081A (et) 1997-10-15

Similar Documents

Publication Publication Date Title
ES2196082T3 (es) Analagos del factor de crecimiento de queratinocitos.
DE69823046D1 (de) Praktische in vitro sialylierung von rekombinanten glykpproteinen
PT94732A (pt) Processo para a preparacao de composicoes contendo um polipeptido da proteina morfogenetica do tecido osseo
ES8608043A1 (es) Un metodo para evitar la formacion de un enlace de disulfuro en una proteina.
DE69133593D1 (de) Menschliches CNP-Gen und Vorläuferprotein
PT96068A (pt) Processo para a producao de proteina biologicamente activa
BR8301918A (pt) Proteina,sequencia de dna,veiculo de expressao replicavel,microorganismo ou cultura celular,plasmideo,composicao,cultura de celulas,utilizacao de tal proteina,processo de expressao,processo para producao de um veiculo de expressao e processo para preparacao de uma proteina uroquinase
ES2127831T3 (es) Unidades de expresion multicistronicas y su aplicacion.
ES2103274T3 (es) Metodo de produccion de proteinas de fusion.
ES2122257T3 (es) Proteinas de fusion de la toxina del antrax y usos de las mismas.
BR9102418A (pt) Proteinas homogenea e de fusao conjugado,processo para conversao de uma prorip em uma rip,isolado de adn,veiculo de expressao e celula hospedeira
ES2120964T3 (es) Peptidos osteogenicos.
MX9302475A (es) Polipeptido de origen no natural que tiene la actividad del factor recombinante de estimulacion del receptor neu y proceso para la produccion del mis mo.
ES548617A0 (es) Procedimiento para disociar peptidos y proteinas en el enla-ce metionilo
AR036449A1 (es) Metodos para sintetizar conjugados polipeptido insulinico-oligomero y conjugados polipeptido proinsulinico-oligomero y metodos para sintetizar dichos conjugados
CY1105763T1 (el) Αναλογα γλυκοπρωτεϊνικων ορμονων δισουλφιδικης σταυρωτης συνδεσης, η παρασκευη και η χρηση τους
ES2068201T3 (es) Produccion de kalicreina.
ES2123582T3 (es) Proteina con capacidad de formacion de huesos y procedimiento para su produccion.
PT1028744E (pt) Utilizcoes neuronais de bmp-11
NO930428L (no) Proteinstrukturen til plantetoksingelonin
PT81528B (pt) Processo para a sintese de peptideos
ES2141819T3 (es) Ligandos del 5-ht1a.
ATE166231T1 (de) Produktion und verwendung von antihelmintischen substanzen und schützenden immunogenen
ES2090357T3 (es) Una proteina de union a colageno asi como su preparacion.
ES8802308A1 (es) Procedimiento para preparar derivados de flaveno o tioflaveno